Monitor closing conditions (auditor concurrence, Series B consent, Nasdaq notification) and subsequent Nasdaq compliance determination. If closed, watch for execution of definitive channel agreements with Cleveland Clinic and AHA, and any stockholder vote on conversion cap removal.
Price Chart
Executive Summary
Vivos Therapeutics issued 12,000 shares of Series C Convertible Preferred Stock (stated value $12M) to acquire an 11% equity stake in SOD Sciences and a 50% co-ownership interest in SOD's pseudohypoxia early-warning test. No cash changes hands; the deal is structured to boost reported stockholders' equity to aid Nasdaq compliance. The transaction is contingent on auditor concurrence, Series B holder consent, and Nasdaq notification, with closing expected on or about October 15, 2026.
Key Financial Metrics
Key Facts
- Vivos issues 12,000 shares of Series C Convertible Preferred Stock with aggregate stated value of $12 million.
- Preferred stock convertible into common at $0.15 per share, representing up to 80 million shares, subject to 19.99% exchange cap and 4.99% beneficial ownership limitation.
- Acquires 11% fully diluted equity interest in SOD Sciences, Inc. and 50% undivided co-ownership interest in SOD's pseudohypoxia early-warning test.
- No cash consideration payable; closing expected on or about October 15, 2026.
- Transaction intended to increase reported stockholders' equity to support Nasdaq compliance efforts.
- Potential collaboration with Cleveland Clinic Weston and marketing relationship with American Health Associates (AHA) covering ~3,000 facilities across 25 states.
- Vivos retains 80% of contribution margin on Vivos product sales through those channels; 50/50 split on jointly owned test sales.
- Clinical utility of the test is not yet established; no assurance of definitive agreements or commercial activity.
Financial Impact
Issuance of $12M stated value preferred stock convertible into up to 80M common shares at $0.15/share; no cash consideration; potential future revenue from test and channel partnerships but no current revenue or margin from the transaction.
Risk Factors
- Transaction may not close if conditions (auditor concurrence, Series B holder consent, Nasdaq notification) are not satisfied.
- Conversion of preferred stock could result in significant dilution (up to 80M shares) if stockholder approval for cap removal is obtained.
- Clinical utility of the pseudohypoxia test is unproven; no assurance of commercial revenue or margin.
- Nasdaq compliance not guaranteed; any increase in stockholders' equity subject to accounting review and Nasdaq assessment.
- Forward-looking statements regarding channel partnerships and revenue are aspirational; no definitive agreements in place.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3381658 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 8-K | $0.1347 | awaiting T+60 | — | $0.1310 (−2.75%) |
Oct 19, 2026 7d ago | Press Release | $0.1410 | awaiting T+60 | — | $0.1310 (−7.09%) |
Oct 19, 2026 7d ago | 8-K | $0.1406 | awaiting T+60 | — | $0.1310 (−6.83%) |
Oct 15, 2026 11d ago | 8-K | $0.1428 | awaiting T+60 | — | $0.1310 (−8.26%) |
Oct 15, 2026 11d ago | Press Release | $0.1428 | awaiting T+60 | — | $0.1310 (−8.26%) |
Sep 30, 2026 26d ago | 8-K | $0.1490 | awaiting T+60 | — | $0.1310 (+12.08%) |
Aug 28, 2026 8w ago | Press Release | $0.2249 | awaiting T+60 | — | $0.1310 (−41.75%) |
Aug 21, 2026 9w ago | 8-K | $0.2768 | awaiting T+60 | — | $0.1310 (−52.67%) |
Aug 14, 2026 10w ago | Press Release | $0.3012 | awaiting T+60 | — | $0.1310 (+56.51%) |
Aug 14, 2026 10w ago | Press Release | $0.3433 | awaiting T+60 | — | $0.1310 (−61.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers